Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Rande Is who wrote (9875)	7/20/1999 11:26:00 AM
From: BANCHEE	Respond to of 57584

Rande Found this On GNLB.. To: PeterSuzman (136 ) From: Henry Niman Tuesday, Jul 20 1999 10:59AM ET Reply # of 138 Doug Sease on CNBC talked about GNLB yesterday. netcognizance.com A synopsis of his report as well as comments on today's price and volume moves are linked to the CNBC Specials table pharmacognizance.com NetCognizance Forum [ Home \| Contents \| Search \| Post \| Reply \| Next \| Previous \| Up ] Doug Sease, Sease On Stocks (Part 2) - GNLB From: M. Bolden Date: 7/19/99 Time: 2:48:34 PM Remote Name: 152.203.236.75 Comments Doug Sease, Sease On Stocks (Part 2) - GNLB GNLB, 1 31/32 up 3/32, is in phase 3 trials with FDA for drug called GL701. The drug is an experimental treatment for lupus. GNLB is also researching drugs that bind to DNA or Rna. GNLB stock is selling below $2, but if one of the drugs it is researching should get approval, the stock has a tremendous upside.